Cinclus Pharma
10.42
SEK
-0.76 %
Less than 1K followers
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-0.76%
-10.94%
-42.37%
-51.26%
-59.19%
-
-
-
-68.04%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
493.83M SEK
Turnover
48.04K SEK
Revenue
4.58M
EBIT %
-3,703.93 %
P/E
-
Dividend yield-%
-
Financial calendar
20.5
2025
Interim report Q1'25
22.5
2025
General meeting '25
20.8
2025
Interim report Q2'25
All
Press releases
ShowingAll content types
Notice of Annual General Meeting in Cinclus Pharma Holding AB (publ)
New scientific article highlights good healing results for Cinclus Pharma's drug candidate linaprazan glurate for the treatment of eGERD
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools